Cargando…
The efficacy and safety of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis
BACKGROUND: We aim to assess the efficacy and safety profiles of immune checkpoint inhibitors in patients with metastatic castration-resistant prostate cancer using a meta-analysis. METHODS: We extracted and examined data from phase I, II and III clinical trials from PubMed, Embase, Web of Science,...
Autores principales: | Wang, Xing-Hui, Wang, Zhi-Qiang, Mu, Zhen-Yu, Zhu, Li-Ping, Zhong, Chong-Fu, Guo, Shanchun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351907/ https://www.ncbi.nlm.nih.gov/pubmed/35945714 http://dx.doi.org/10.1097/MD.0000000000029715 |
Ejemplares similares
-
Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
por: Lanka, Sree M., et al.
Publicado: (2023) -
Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2021) -
Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer
por: Zhang, Xuebao, et al.
Publicado: (2019) -
Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic
Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017) -
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)